KRAS and pancreatic ductal adenocarcinoma: Recently, BCAA metabolism in many cancers has attracted substantial attention.9,11–13,32 However, BCAA metabolism plays various functional roles in different cancer types, which may be determined by both tissue-of-origin and oncogenic mutations.33 The KRAS oncogene is a driver mutation, and ~90% of pancreatic ductal adenocarcinomas have KRAS mutations.